Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease

Cubo, E.; Gonzáles, M.; del Puerto, I.; de Yébenes, J. G.; Arconada, O. F.; Gabriel y Galàn, J. .M; Nirkko, Arto Christian; European Huntington's Disease Initiative Study Group, (2012). Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease. Movement disorders, 2012(27), pp. 439-442. Hoboken, N.J.: Wiley-Blackwell 10.1002/mds.24062

Text PlaceboEffect_NirkkoStudyGroup.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (864kB) | Request a copy

BACKGROUND Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington's disease. METHODS Placebo data were obtained from an international, longitudinal, placebo-controlled trial for Huntington's disease (European Huntington's Disease Initiative Study Group). One-hundred and eighty patients were evaluated using the Unified Huntington Disease Rating Scale over 36 months. A placebo effect was defined as an improvement of at least 50% over baseline scores in the Unified Huntington Disease Rating Scale, and clinically relevant when at least 10% of the population met it. RESULTS Only behavior showed a significant placebo effect, and the proportion of the patients with placebo effect ranged from 16% (first visit) to 41% (last visit). Nondepressed patients with better functional status were most likely to be placebo-responders over time. CONCLUSIONS In Huntington's disease, behavior seems to be more vulnerable to placebo than overall motor function, cognition, and function

Interest & Impact

Downloads

0 since deposited on 04 Oct 2013
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item